Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica

키워드

참고문헌 (33)

1. Tan CS, "Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis", Lancet Neurol, 9, pp.425~437 (2010)[DOI]
2. Engels EA, "Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma", Int J Cancer, 117, pp.1013~1019 (2005)[DOI]
3. Tan CS, "JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy", J Virol, 84, pp.9200~9209 (2010)[DOI]
4. Komagome R, "Oligosaccharides as receptors for JC virus", J Virol, 76, pp.12992~13000 (2002)[DOI]
5. Fonseca MI, "Distribution of serotonin 2A, 2C and 3 receptor mRNA in spinal cord and medulla oblongata", Brain Res Mol Brain Res, 89, pp.11~19 (2001)[DOI]
6. Koralnik IJ, "Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name?", Ann Neurol, 60, pp.162~173 (2006)[DOI]
7. Bauer J, "Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS)", Acta Neuropathol, 130, pp.751~764 (2015)[DOI]
8. McGuigan C, "Stratification and monitoring of natalizumabassociated progressive multifocal leukoencephalopathy risk: recommendations from an expert group", J Neurol Neurosurg Psychiatry, 87, pp.117~125 (2016)[DOI]
9. Misbah SA, "Progressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency", Clin Exp Immunol, 188, pp.342~352 (2017)[DOI]
10. Clavel G, "Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments", Joint Bone Spine, 84, pp.671~675 (2017)[DOI]
11. Bellizzi A, "New insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathy", Clin Dev Immunol, 2013, pp.839719~ (2013)
12. Moher D, "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement", J Clin Epidemiol, 62, pp.1006~1012 (2009)[DOI]
13. Lee P, "A second-generation ELISA (STRATIFY JCVTM DxSelectTM) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification", J Clin Virol, 57, pp.141~146 (2013)[DOI]
14. Bozic C, "Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1", Ann Neurol, 70, pp.742~750 (2011)[DOI]
15. Olsson T, "Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort", Mult Scler, 19, pp.1533~1538 (2013)[DOI]
16. Bozic C, "Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial", Eur J Neurol, 21, pp.299~304 (2014)[DOI]
17. Fragoso YD, "Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive", Arq Neuropsiquiatr, 71, pp.780~782 (2013)[DOI]
18. Bhan V, "Anti-JC virus antibody prevalence in Canadian MS patients", Can J Neurol Sci, 41, pp.748~752 (2014)[DOI]
19. Kolasa M, "Anti-JC virus seroprevalence in a Finnish MS cohort", Acta Neurol Scand, 133, pp.391~397 (2016)[DOI]
20. Outteryck O, "Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy", J Neurol, 259, pp.2293~2298 (2012)[DOI]
21. Schwab N, "Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values", Neurol Neuroimmunol Neuroinflamm, 3, pp.e195~ (2016)[DOI]
22. Trampe AK, "Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort", Neurology, 78, pp.1736~1742 (2012)[DOI]
23. Alroughani R, "JC virus seroprevalence and seroconversion in multiple sclerosis cohort: a Middle-Eastern study", J Neurol Sci, 360, pp.61~65 (2016)[DOI]
24. Lanzillo R, "JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level", Ther Clin Risk Manag, 10, pp.807~814 (2014)
25. Delbue S, "JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients", J Neurovirol, 21, pp.645~652 (2015)[DOI]
26. Kim SH, "Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder", J Neurol, 262, pp.696~700 (2015)[DOI]
27. Lamdhade S, "Prevalence of Anti-JC virus antibody in multiple sclerosis patients in Kuwait", ISRN Neurol, 2014, pp.861091~ (2014)
28. Vennegoor A, "High cumulative JC virus seroconversion rate during long-term use of natalizumab", Eur J Neurol, 23, pp.1079~1085 (2016)[DOI]
29. Correia I, "Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population", J Clin Neurosci, 45, pp.257~260 (2017)[DOI]
30. Aladro Y, "Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain", J Neurol Sci, 365, pp.16~21 (2016)[DOI]
31. Dominguez-Mozo MI, "Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort", Eur J Clin Invest, 47, pp.158~166 (2017)[DOI]
32. van Kempen ZLE, "John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients", Eur J Neurol, 24, pp.1196~1199 (2017)[DOI]
33. Schwab N, "Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters", Mult Scler (2017)

관련 논문AI추천